Breast Cancer

Consuming a diet high in fiber was linked with a reduced incidence of breast cancer in an evaluation of all relevant studies, according to findings published in CANCER.

Cases studies focused on medication reconcilliation for patients with breast cancer.

Oncology pharmacists can prevent errors that occur when a patient’s medications include prescription drugs, OTC medications, herbals, and dietary supplements.

A new blood test has detected more than 50 types of cancer as well as their location within the body, according to an international team of researchers led by the Dana-Farber Cancer Institute and the Mayo Clinic.

New research in 5 human cancer cell lines revealed interdependencies between a tumor and its host’s microenvironment.

Genomic profiles measured through circulating free DNA in the blood of patients with breast cancer may provide a more effective way to treat the disease and track its progression.

Researchers examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.

The researchers plan to present updated data at the European Society for Medical Oncology Breast Cancer conference in May.

New information from the IQVIA “Global Medicine Spending and Usage Trends” report highlights the expected growth of specialty pharmacy spending by 2024.

DCIS is a noninvasive condition in which abnormal cells are found in the lining of a breast duct but have not spread to other tissues in the breast.

New research has examined the details surrounding the signaling molecule interleukin-2, which could lead to more targeted therapies for diseases such as cancer.

Guidelines recommend that Ashkenazi Jewish women discuss genetic testing with physicians, but other women with breast cancer are less likely to receive a recommendation of testing.

Research may lead to the development of new types of binding proteins for biological sugar structures, which play a significant role in cancer and infectious diseases.

Patients with a history of cancer have a greater likelihood of developing atrial fibrillation, the most common heart rhythm disorder, compared with the general population.

The new study has found that the lymphedema monitoring technology, marketed by LymphaTech, can effectively detect early arm swelling associated with lymphedema in breast cancer patients.

Trastuzumab-dttb was first approved in January 2019 across all eligible indications, mainly adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer.

The growth of the pipeline has led to increases in insurance carriers’ specialty plan spend.

Statins, widely used to lower cholesterol and prevent heart disease, may guard against heart damage caused by certain breast cancer therapies.

“We’re pretty devastated,” said Jessica Harris, a friend of Rutter, in an interview with WFSB. “She beat cancer and lost the battle to coronavirus—it’s just crazy.”

A new study shows that the advantages of digital breast tomosynthesis are maintained over multiple years and rounds of screening compared with digital mammography.

A growth hormone known as insulin-like growth factor-1 has been found to play a role in the development of breast cancer.

AL101 is a potent, selective, injectable small molecule gamma secretase inhibitor and was granted Orphan Drug designation in May 2019 for the treatment of ACC.

Melissa B. Armitage, PharmD, BCOP, a clinical pharmacist who works in breast oncology at the Moffitt Cancer Center in Tampa, Florida, discussed this disease's pathophysiology, natural progression, and risk factors.

Depending on the amount consumed, intake of dairy milk can increase the risk of breast cancer by up to 80%, according to new research from Loma Linda University Health.

Officials from the FDA have approved a supplemental New Drug Application (sNDA) for neratinib (NERLYNX, Puma Biotechnology) in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer that have received 2 or more prior anti-HER2-based regimens in the metastatic setting.

HER2 is a membrane-bound tyrosine kinase that when amplified contributes significantly to a tumor’s ability to proliferate and survive.

In the pivotal phase 3 KEYNOTE-355 study, pembrolizumab (Keytruda, Merck) combined with chemotherapy met one of its dual primary endpoints of progression-free survival (PFS) as a first-line treatment for patients with metastatic triple-negative breast cancer (TNBC) whose tumors expressed programmed death-ligand 1 (PD-L1).

A combination therapy may counter the resistance to human epidermal growth factor receptor 2 inhibitor neratinib in patients with breast, ovarian, lung, or other cancers.

The study was the first to examine proton pump inhibitors use in breast cancer survivors.

Margetuximab plus chemotherapy showed positive results in a second pre-specified interim overall survival analysis for the phase 3 SOPHIA study.